Effect of finasterid on COVID-19 treatment

Investigation of the effect of "Finasterid" on the prognosis in the hospitalized over 50 years male patients with COVID-19 pneumonia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200505047318N1

Enrollment

Registered

2020-08-06

Start date

2020-03-20

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Corona virus pneumonia. COVID-19,virus not identified

Interventions

Intervention 1: Intervention group :Tab.HCQ 200,Po,Q12h/Amp.Ceftriaxon,1 gr,IV.Q12h/ TTab.finasteride 5mg,PO,Daily,5 days. Intervention 2: Control group:Tab.HCQ 200,Po,Q12h/Amp.Ceftriaxon,1 gr,IV.Q12h

Eligibility

Sex/Gender

Male

Age

50 Years to No maximum

Inclusion criteria

Inclusion criteria: having covid-19 age>50 years male hospitalization

Exclusion criteria

Exclusion criteria: use finasterid before covid-19 neurologic disease psychiatric disease drug users

Design outcomes

Primary

Measure	Time frame
O2 saturation of blood. Timepoint: initial/fifth day of hospitalization. Method of measurement: pulse oximeter.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Abbas Allami

Qazvin University of Medical Sciences

allami@qums.ac.ir+98 28 3333 2930

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 15, 2026